Reading Time: 3 minutes This blog is part of the ‘Highlights from Glasgow’ collection of articles, where you can read about the content of some of the talks and posters presented at the 29th International Symposium on ALS/MND. In the Clinical trials and trial design (4B) session we heard from two speakers looking at ways to improve current design…
Reading Time: 4 minutes At this time of year, it’s always good to look back on the previous year to see just how far we’ve really come. We’re pleased to say that 2012 was full of progress being made in the world of MND research and we hope that the speed and number of exciting findings being announced continues…
Reading Time: 3 minutes A very much ‘must report on’ session of the 23rd International Symposium on ALS/MND was the clinical trials and trial design session. There are many reasons that make this an interesting session – perhaps the most eagerly anticipated were the presentations on the NP001 study and the results of the stem cell safety trial: NP001…
Reading Time: 3 minutes Promising results from a Phase II clinical trial for a drug called NP001 have been announced by the biopharmaceutical company Neuraltus. The trial, conducted in America, suggested that NP001 is safe, well tolerated and could be beneficial for MND. Following these encouraging results, Neuraltus plan to begin a larger, Phase III trial of NP001 in the second half…
Reading Time: 3 minutes “After a time where patients and sponsors of trials alike had become disheartened about the lack of positive clinical trials, it is exciting to see so many positives, including the recently approved Neudexta, and the dexpramipexole study”, commented Professor Robert Miller from the Forbes Norris ALS/MDA centre in San Francisco opening the discussions on clinical…
Reading Time: 9 minutes I’m sure many of you who follow our blog have also been following the discussion on our forum about the Neuraltus trial for a drug called NP001. First of all, thanks to ‘Matt J’ for initially raising this issue on our forum. It highlights the power of the forums in facilitating information spread and getting new news…
